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Introduction
In the wake of an era where high throughput screening of large sets of compounds (2-4 M) has failed to translate into increased success in the clinic, a paradigm shift in screening has emerged, moving from an emphasis on relatively simple and low-cost high throughput screens to more biologically relevant and potentially complex screens of focused sets of compounds. In the nascent scenario, a focused screen of 10 2 -10 5 compounds is often followed by an additional screen of compounds, selected based on a machine learning algorithm trained on the results from the initial library. This iterative approach ideally affords chemical starting points for a drug discovery program that perturb a more biologically relevant system, and the hope is that screening in more physiologically relevant and translatable assays will translate into greater success in the clinic. In the present report, we describe a high throughput screen (HTS) of 3 M compounds against alanine-serine-cysteine transporter-1 (Asc-1). In addition, we conducted an iterative focused screen (IFS) employing a more biologically relevant screening format. The IFS was initiated by a smaller set of diverse compounds (45 K compounds) that was followed by one step of expansion (15K compounds) selected based on machine learning. We identified tool compounds using both approaches, and offer a unique comparison of the screening paradigms.
The role of Asc-1 in regulating synaptic D-serine levels, and thereby affecting N-methyl-D-aspartate receptor (NMDAR) function
(1) , makes it a potentially attractive target for therapies relating to cognitive function (2) . Asc-1 knock-out studies implicate the transporter as a critical regulator of synaptic D-serine levels (3) . Additional studies demonstrate that increasing D-serine levels mitigates schizophrenic behaviors in animal models. (4) Several small molecule Asc-1-selective inhibitors have been developed with differing mechanisms of action, and recent studies have suggested that inhibition of Asc-1 may paradoxically result in reduced, rather than increased, levels of D-serine.
(5-7) Asc-1 (encoded by SLC7A10 gene) is the "light unit" of a heterodimeric amino-acid transporter (where transport activity takes place), which also contains the "heavy unit" 4F2 cell-surface antigen heavy chain (4F2hc, encoded by the SLC3A2 gene). It is a Na + -independent amino acid transporter with homology to the system L transporter (LAT) family. (8, 9) Although Asc-1 exhibits high affinity for small, neutral L-amino acids such as alanine, it also has high affinity for D-amino acids, including D-serine, (8) (9) (10) a co-agonist of NMDAR. (11) Asc-1 is widely distributed throughout the brain, largely localized to presynaptic nerve terminals (10) but in significant overlap with brain regions expressing and releasing D-serine from glial cells. (12) We initially sought to identify selective inhibitors of Asc-1 by developing an assay that would support a screen of our full compound collection (~3 M compounds). Although radiolabelled amino acid uptake is a well-tested method for examining transporter function including Asc-1, (5) (6) (7) developing a cell line and an assay detection format robust enough for a miniaturized (1536-well plate based) approach was a significant challenge. We describe a radiotracer uptake screening strategy using whole cells (heterologously expressing Asc-1) adherent to scintillation proximity assay (SPA) beads with [ 35 S]-cysteine as a surrogate for D-serine. In addition we incorporated off-target assays, including uptake in parental cells and a cytotoxicity assay, to mitigate potential false-positives that affected non-specific amino acid uptake and cell viability, respectively. Based on a subsequent comparison of the SPA assay with a more biologically relevant [ 3 H]-D-Serine uptake inhibition assay against a set of previously untested compounds, we were concerned that the assay might have missed relevant and attractive chemical matter. This propelled us to perform an IFS on the lower throughput, but more biologically relevant assay in a 384 well format. Off-target assays were also incorporated into this approach to inform the subsequent machine learning models. The focused screen (45 K compounds) was followed up with an expansions step (15 K compounds), based on compounds selected for screening from our entire compound collection using naïve Bayesian models.
Machine learning models such as random forest or naïve Bayesian have proven to be valuable in selecting compounds for screening based on a previous focused screen. (13, 14) In many retrospective analyses of IFS, full deck screening data is used to validate models, and the hits obtained from a focused set followed by several expansion steps are compared to the total hits obtained by the full deck screen. (13, 15, 16) In practice, however, this is usually not a feasible approach, and only 1-3 steps of expansion are performed.
(13) Here, we built two models on the initial 45 K focused screen, and selected 7.5 K compounds with each model. For one model we used chemical descriptors (ECFP4 (17) ), and for the other model we used biological descriptors (HTS fingerprints (18) ). While there may be some overlap in the compounds that are identified with the two approaches, we anticipated that they would complement each other and result in a broader coverage of the active chemical matter. (14, 15, 18) In addition to the information captured in the screen (active/inactive) we also included compounds in the "inactive" category that contained chemotypes that we wanted to avoid, previously identified as undesirable by the project team during the work up of the full deck HTS screen. This approach allowed us to compare, head to head, models trained on either chemical or biological descriptors, in a prospective manner. This is the largest prospective comparison of chemical versus biological expansion for a single assay to date.
In the present report, we seek to address three questions: 1) After previously running and working up a full deck screen against a challenging target such as Asc-1, can a screen aimed at the same target but using a more relevant biological format yield novel chemical matter that can serve as drug leads? 2) How does expansion of an initial screen based on chemical structural fingerprints compare to expansion based on biological fingerprints? 3) How do the small molecule tools identified using a focused approach compare to the previously identified compounds from the full HTS?
Results and Discussion
Optimization of HTS SPA Assay for Asc-1 Inhibition. The first strategy to identify novel inhibitors of Asc-1 relied on the ability to screen our company's 3 M compound library in a 1536 well format. Although the measurement of D-serine would be more biologically relevant as the natural substrate of Asc-1 relevant to NMDAR modulation, this amino acid can only be labelled with the relatively weak beta emitter 3 H. The lower energy radioactive decay requires screening methods that are less efficient (see Methods). In contrast, a combination of a higher energy beta decay isotope ( 35 S) on a surrogate sulfur-containing amino acid, cysteine, in combination with SPA beads would potentially enable a higher-density screening format. The SPA imaging bead format ( Figure 1A ) was examined with whole-cells stably expressing Asc-1 and mediating uptake of [ 35 S] cysteine to achieve a sufficient assay window. (6) Initial assay development was performed in a 384 well plate format, and Asc-1-specific uptake of [ 35 S] cysteine was established with inhibition by 10 mM D-serine, relative to total uptake determined by inhibition with 1 mM cold cysteine. Optimal SPA bead coating was determined to be poly-L-lysine rather than wheat germ agglutinin ( Figure S1A ). Incubation times were also explored ( Figure S1B ), identifying an optimal incubation time to maximize Asc-1-specific [ 35 S] cysteine uptake between 12 -19 minutes (Figure S1B Inset). The assay window was further improved by addition of other amino acids to suppress non-Asc-1 dependent transport ( Figure S1C ). Although L-phenylalanine appeared to give the largest window, it also increased background and was difficult to solubilize, so Lglutamine was selected instead. Subsequent optimization steps were performed to achieve the final 10 μL per well 1536 well plate format as summarized in Figure S1D . S L-cysteine, radioactive amino acid is concentrated inside the cell, enabling energy transfer from radioactive decay to the scintillation bead which emits light that is detected by the plate imager. B. HTS screening funnel for full deck screen is shown indicating different assays by outline color and different stages: primary, confirmation/counter, concentrationresponse. Numbers of compounds screened at each step are indicated on the left and a brief summary of selection criteria are indicated on the right. CR indicates concentration-response performed with 8 concentrations at 3-fold dilution. C. Concentration-titration data from Compound 1 representing a desirable profile emerging from the screening funnel in B. Note that the data colors correspond to the assay outline color in B. Lines indicate best fit to Equation 1 for titrations that could be fit.
HTS SPA Assay for 3 M Compounds. High-throughput screening of the full compound collection at 10 μM final concentration (n = 1) spanned 2374 plates with an average signal-to-baseline of 2.6 ± 0.5 fold and Z' 0.40 ± 0.12 ( Figure S2 A, B) . Plates containing titrations of previously identified non-amino acid small molecule inhibitors of Asc-1 were tested throughout the primary screen by including these plates in runs of 100 -120 compound collection plates ( Figure S2 C, D) . Monitoring these positive controls to confirm that they were also active in the assay allowed an additional qualitative assessment of assay quality beyond the intraplate positive (10 mM D-Serine) and negative (DMSO alone) controls. Hits from the screening campaign were selected based on four different measurements: % Activity, Zscore, Adjusted %Activity and B-score, with the latter two measurements reflecting corrections for systematic spatial adjustments during the assay. (19) An additional culling of the list was done to identify compounds with desirable properties (molecular weight < 650, approximate ligand binding efficiency > 11). A set of 60,000 compounds were tested in triplicate in the primary screening assay (confirmation) as well as an off-target, non-Asc-1 mediated uptake assay in CHO-K1 cells (counter screen, Fig 1B) . Compounds with confirmed activity, lack of activity in the counter screen, and desirable physical chemical properties (15 K) were selected for 8 point titration testing in the Asc-1 and non-Asc-1 uptake assays as well as a cytotoxicity assay (Fig 1B) . In an additional round of follow up, 2500 compounds were subjected to a 384 well plate [ 3 H]-D-Serine uptake assay, a rat Asc-1 assay to confirm activity on a species for in vivo profiling, and a human LAT-2 assay to identify compounds that broadly inhibit the system L transporter family. Figure 1C illustrates activity data from a compound (Compound 1) with a desirable profile emerging from the screening plan illustrated in Figure 1B , exhibiting a concentrationdependent effect on Asc-1 uptake in both the [ ]-D-Serine uptake assay was better correlated with ex vivo or in vivo Asc-1 inhibitor activity across a wide set of compounds, D-serine uptake had been employed in other prior screening efforts to identify such inhibitors (6) . Figure 3A) . Assay optimization was performed to adapt to a fullyautomated 384 well format ( Figure S3) . A structurally diverse collection of ~45 K compounds was employed in the initial round of screening. Importantly, a counter screen was incorporated into the screening strategy. Initially, [ 3 H]-D-Serine uptake in a CHO-K1 line lacking Asc-1 expression was explored; however, there was insufficient signal window to utilize this assay approach (data not shown). Instead, using measurement of [ 3 H]-L-tyrosine uptake in CHO-K1 cells in a parallel 384-well, plate-based scintillation assay format exhibited sufficient assay window to eliminate false positives due to nonspecific inhibition of amino acid uptake ( Figure S4 ). In order to be considered a "hit," a compound had to demonstrate >50% [ ]-L-tyrosine uptake uptake inhibition (counterscreen), and a 20% difference between the two values (to ensure specificity). These criteria proved quite stringent, and a hit rate of 0.26% was obtained in the initial screen.
Following further confirmation of the initial hits, an expansion of hits was performed using two different modeling approaches, one based on 2D chemical fingerprints, and one based on biological fingerprints. For both models, in addition to using the actives and inactives from the 45 K screen in training, undesirable compounds from the original full collection HTS SPA assay were also included in the "inactive" category, to avoid rediscovery of these chemotypes during the expansion step. For each model, the top scoring 7.5 K compounds were selected from our company's screening collection (see methods), totaling ~15 K compounds. Out of 7.5 K compounds selected by each method, 363 compounds (~5%) were identified by both methods. When the 15 K compounds were screened in the expansion step, there were 600 hits, a hit rate of 4.2 % (16-fold enrichment over the initial screen; same hit criteria as above). Interestingly, if the two models are considered separately, the hit rates were nearly identical (4.7 % for ECFP4, 4.6% for HTS-FP; hit rates are higher here due to the slight overlap of the selected compounds). H] D-serine. Again, the radioactive amino acid is concentrated inside the Asc-1 expressing cells; however, a wash step is required to remove the extracellular material. This step is followed by cell lysis and addition of scintillant to detect the weaker beta emissions from the remaining [ Biological versus Chemical-Based Expansion. We were curious how the two methods compared in terms of navigating chemical space from the initial hits. We employed a Non-Linear Map (NLM) to visually compare the chemical space occupied by the expansion sets based on chemical descriptors (blue) and biological descriptors (yellow) with the initial hits (red, Figure 4A ). In this type of a representation, compounds that are aggregated near each other are structurally similar, though distances between various clusters of compounds are not meaningful. We noticed that in many cases, clusters obtained from chemical expansion were clustered together with one of the initial hits, whereas many of the biological clusters were devoid of any initial hits. This is not entirely surprising, since the biological expansion is entirely agnostic of chemical structure. Tanimoto similarity of each of the hits from the 15 K screen is compared to their nearest neighbor in the initial set of hits obtained from the 45 K screen. While hit rate were the same for each method, biological expansion identified chemical matter that is more distant from initial hits (lower Tanimoto similarity).
We then focused on the hits obtained from the expansion (Fig 4B) . From this perspective, it is clear that we obtained diverse chemical matter to follow up on after expansion (i.e., the hits were not coming from only a few clusters). We also observed that although there was some overlap in the chemical matter that was obtained from the two methods (green, Fig 4B) , the two methods were complementary and by employing both approaches, a greater diversity of chemical starting points was obtained. We highlight four of the largest clusters that were enriched in hits and their corresponding representative Bemis-Murcko scaffold (Fig 4C) . (20) We see that clusters are indeed grouped together on the NLM. Furthermore, we can see that some clusters are dominated by chemical expansion (cluster 2), while other clusters are dominated by biological expansion (cluster 21).
To further assess the similarity of the expanded hits compared to the initial hits, we plotted the maximum similarity of the expanded hits obtained either by chemical (ECFP4) expansion or biological (HTS-FP) expansion in relation to the initial hits (Fig 4D) . It is clear from this plot that although both methods had equal hit rates, biological expansion identified active chemical matter that tended to be distinct from the initial hits. We also compared the biological similarity (HTS-FP Pearson Correlation) of the expansion hits with the initial hits, revealing that in general, as might be expected, the biological similarity was greater for the expansion compounds obtained by biological (HTS-FP) expansion ( Figure  S5 ).
Asc-1 Tool Compounds.
While several series were explored based on the expansion, two series yielded especially promising tools for Asc-1. These are represented by compound 2 and 3 (Fig 5) . Of note, while there was no bias towards compounds obtained from either expansion in follow up experiments (squares in Fig 4B) , both of these compounds were obtained through biological expansion of the initial hits (Fig 4B) . Compound 2 was a singleton while compound 3 was in a cluster of two compounds, both of which were active and identified through biological expansion. In Figure 5 , we compare their profiles to that of a representative compound obtained through the initial HTS SPA assay. It is clear that they offer distinct chemotypes for Asc-1. Furthermore, their activity in the [ 3 H] D-serine uptake Asc-1 screen is comparable to the HTS derived compound. Importantly, compounds 2 and 3, as well as a more potent analogue of Compound 1 (structure not provided), were active in a rat hippocampal neuron assay ( Figure 6 ). Even so, other undesirable properties present in the HTS hit 1 (low solubility, high AlogP) were also present in compounds 2 and 3, which highlights the challenging nature of identifying drug like chemical matter for the Asc-1 amino acid transporter. Despite these challenges several analogues from the Compound 1 chemical series were explored in in vivo models that will be part of a subsequent publication. show an inflection point up to the dose tested (>23.9 uM), with 43.4% inhibition at 23.9 uM (n=2, blue squares), and Compound 3 showed an inflection point of inhibition at 7.109 uM, with 80.3% inhibition at 23.9 uM (n=2, green triangles).
Conclusions.
Our work has laid a precedent for the value in re-mining a sample collection with a more biologically relevant lower throughput screen, after a high throughput screen has already been executed on the same collection. During the IFS, we compared chemical versus biological expansion, and conclude that it is imperative that both types of models are employed in order to maximally explore chemical space during expansion steps. Through our campaigns, we have identified three Asc-1 tools that are distinctive from literature tools and can be used by research teams to further understand Asc-1 biology.
Methods
Scintillation Proximity Assay (SPA) Imaging Bead Assay: Chinese Hamster Ovary (CHO) cells stably expressing human Asc-1/4F2hc (SLC7A10/SLC3A2) were maintained in F12 media with GlutaMAX and 10 % heat inactivated fetal bovine serum (Life Technologies) with 1 mg/mL geneticin and 250 ug/mL zeocin (both from Invitrogen). Cells were harvested with TrpLE (Life Technologies) and resuspended at 2x10 S Lcysteine (Perkin Elmer, No. NEG022T, 1075 Ci/mmol, at 25 -35 nM, 2.5 -3.5 nM final with cold Lcysteine added to reach 100 nM total L-cysteine). The final volume of the entire reaction was 10 uL per well. Following 13 min incubation at room temperature, the plate was spun (VSpin, Agilent) and imaged on a ViewLux (PerkinElmer, SPA Red Shift Luminescence, 2X bin, emission 613 nm).
The counter screen followed the protocol above with the following changes: a) CHO-K1 cells were used instead of human Asc-1 expressing cells, b) glutamine was NOT added to the assay buffer, c) 1 mM L-cysteine was used instead of 10 mM D-Serine to determine 100 % inhibition.
